KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $37.2 million.

  • CRISPR Therapeutics AG's Cash from Investing Activities fell 6484.96% to $37.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$31.8 million, marking a year-over-year increase of 8866.06%. This contributed to the annual value of -$31.8 million for FY2025, which is 8866.06% up from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Cash from Investing Activities stood at $37.2 million, which was down 6484.96% from -$119.2 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's Cash from Investing Activities' 5-year high stood at $216.9 million during Q2 2023, with a 5-year trough of -$565.2 million in Q3 2021.
  • Its 5-year average for Cash from Investing Activities is -$61.6 million, with a median of -$68.8 million in 2022.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Cash from Investing Activities crashed by 804524.27% in 2021, and later surged by 48686.51% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Cash from Investing Activities (Quarter) stood at -$8.7 million in 2021, then crashed by 1913.91% to -$175.5 million in 2022, then soared by 53.6% to -$81.5 million in 2023, then skyrocketed by 229.93% to $105.8 million in 2024, then tumbled by 64.85% to $37.2 million in 2025.
  • Its Cash from Investing Activities was $37.2 million in Q4 2025, compared to -$119.2 million in Q3 2025 and $70.0 million in Q2 2025.